Feasibility Of Administering Adjuvant Chemotherapy Of Pemetrexed Followed By Pemetrexed/oxaliplatin Immediately Post-VATS In Patients With Completely Resected NSCLC
Affiliations
- PMID:22263005
- PMCID: PMC3256481
Item in Clipboard
Feasibility Of Administering Adjuvant Chemotherapy Of Pemetrexed Followed By Pemetrexed/oxaliplatin Immediately Post-VATS In Patients With Completely Resected NSCLC
Jianxing He et al. J Thorac Dis.2009 Dec.
Display options
Format
Display options
Format
Abstract
Non-small cell lung cancer (NSCLC) accounts for the largest number of cancer deaths annually, worldwide. It seems reasonable to test a less toxic regimen also in early stages after complete (R0) resection of the tumor, where reduced toxicities might improve the feasibility of drug delivery, compliance and the convenience of treatment for the patient and hence perhaps improve survival. The main purpose of this phase II trial is to evaluate the clinical feasibility-in terms of patients without dose limiting toxicities or premature treatment withdrawal or death-of administering adjuvant chemotherapy of pemetrexed followed by pemetrexed/oxaliplatin immediately post-VATS (video-assisted thoracic surgery) in patients with completely resected NSCLC.
Keywords: adjuvant chemotherapy; non-small cell lung cancer; oxaliplatin; pemetrexed; video-assisted thoracic surgery.
Conflict of interest statement
The authors have no commercial, proprietary, or financial interest in the products or companies described in this article.
Similar articles
- Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol.Kreuter M, Vansteenkiste J, Griesinger F, Hoffmann H, Dienemann H, De Leyn P, Thomas M.Kreuter M, et al.BMC Cancer. 2007 May 8;7:77. doi: 10.1186/1471-2407-7-77.BMC Cancer. 2007.PMID:17488518Free PMC article.Clinical Trial.
- Three-Year Follow-Up of a Randomized Phase II Trial on Refinement of Early-Stage NSCLC Adjuvant Chemotherapy with Cisplatin and Pemetrexed versus Cisplatin and Vinorelbine (the TREAT Study).Kreuter M, Vansteenkiste J, Fischer JR, Eberhardt WE, Zabeck H, Kollmeier J, Serke M, Frickhofen N, Reck M, Engel-Riedel W, Neumann S, Thomeer M, Schumann C, De Leyn P, Graeter T, Stamatis G, Griesinger F, Thomas M; TREAT investigators.Kreuter M, et al.J Thorac Oncol. 2016 Jan;11(1):85-93. doi: 10.1016/j.jtho.2015.09.014.J Thorac Oncol. 2016.PMID:26762743Clinical Trial.
- A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer.Schmid-Bindert G, Engel-Riedel W, Reck M, Schuette W, Stöhlmacher J, Fischer JR, Mazières J, Chouaid C, Wolf M, Vinolas N, Soldatenkova V, Ripoche V, Nguyen T, Visseren-Grul C.Schmid-Bindert G, et al.Lung Cancer. 2015 Dec;90(3):397-404. doi: 10.1016/j.lungcan.2015.11.007. Epub 2015 Nov 7.Lung Cancer. 2015.PMID:26791798Clinical Trial.
- Pemetrexed use in the adjuvant setting for completely resectable non-small-cell lung cancer.Simon GR, Manegold C, Barker SS, Treat JA, Visseren-Grul C, Obasaju C.Simon GR, et al.Clin Lung Cancer. 2013 Nov;14(6):601-8. doi: 10.1016/j.cllc.2013.06.001. Epub 2013 Aug 6.Clin Lung Cancer. 2013.PMID:23921171Review.
- The evolving role of pemetrexed (Alimta) in lung cancer.Socinski MA, Stinchcombe TE, Hayes DN.Socinski MA, et al.Semin Oncol. 2005 Apr;32(2 Suppl 2):S16-22. doi: 10.1053/j.seminoncol.2005.02.008.Semin Oncol. 2005.PMID:15818533Review.
Cited by
- VATS lobectomy facilitates the delivery of adjuvant docetaxel-carboplatin chemotherapy in patients with non-small cell lung cancer.Zhi X, Gao W, Han B, Yang Y, Li H, Liu D, Wang C, Min G, Long H, Rigas JR, Carey M, Jahan T, Sammann A, Reza J, Wang D, Mann MJ, Jablons DM, He J; China Clinical Trials Consortium.Zhi X, et al.J Thorac Dis. 2013 Oct;5(5):578-84. doi: 10.3978/j.issn.2072-1439.2012.02.05.J Thorac Dis. 2013.PMID:24255769Free PMC article.
- Is T790M mutation the key in development of resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)?Takabe K.Takabe K.J Thorac Dis. 2011 Mar;3(1):1-3. doi: 10.3978/j.issn.2072-1439.2011.01.06.J Thorac Dis. 2011.PMID:22263056Free PMC article.No abstract available.
References
- Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–92. - PubMed
- Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997;111:1710–7. - PubMed
- Tada H, Tsuchiya R, Ichinose Y, Koike T, Nishizawa N, Nagai K, Kato H. A randomized trial comparing adjuvant chemotherapy versus surgery alone for completely resected pN2 non-small cell lung cancer (JCOG9304) Lung Cancer. 2004;43:167–73. - PubMed
- Scagliotti GV, Fossati R, Torri V, Crinò L, Giaccone G, Silvano G, et al. Adjuvant Lung Project Italy/European Organisation for Research Treatment of Cancer-Lung Cancer Cooperative Group Investigators Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst. 2003;95:1453–61. - PubMed
- Waller D, Peake MD, Stephens RJ, Gower NH, Milroy R, Parmar MK, et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg. 2004;26:173–82. - PubMed
Related information
LinkOut - more resources
Full Text Sources